In Vivo Sensitized and In Vitro Activated B Cells Mediate Tumor Regression in Cancer Adoptive Immunotherapy

被引:99
作者
Li, Qiao [1 ]
Teitz-Tennenbaum, Seagal [1 ]
Donald, Elizabeth J. [1 ]
Li, Mu [1 ]
Chang, Alfred E. [1 ]
机构
[1] Univ Michigan, Ctr Comprehens Canc, Div Surg Oncol, Ann Arbor, MI 48109 USA
基金
美国国家卫生研究院;
关键词
ANTIGEN-PRESENTING CELLS; CD8(+) T-CELLS; ANTITUMOR REACTIVITY; MURINE MODEL; RESPONSES; EFFICACY; MELANOMA; THERAPY; MICE; LYMPHOCYTES;
D O I
10.4049/jimmunol.0803773
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Adoptive cellular immunotherapy utilizing tumor-reactive T cells has proven to be a promising strategy for cancer treatment. However, we hypothesize that successful treatment strategies will have to appropriately stimulate not only cellular immunity, but also Immoral immunity. We previously reported that B cells in tumor-draining lymph nodes (TDLNs) may function as APCs. In this study, we identified TDLN B cells as effector cells in an adoptive immunotherapy model. In vivo primed and in vitro activated TDLN B cells alone mediated effective (p < 0.05) tumor regression after adoptive transfer into two histologically distinct murine pulmonary metastatic tumor models. Prior lymphodepletion of the host with either chemotherapy or whole-body irradiation augmented the therapeutic efficacy of the adoptively transferred TDLN B cells in the treatment of s.c. tumors as well as metastatic pulmonary tumors. Furthermore, B cell plus T cell transfers resulted in substantially more efficient antitumor responses than B cells or T cells alone (p < 0.05). Activated TDLN B cells conferred strong humoral responses to tumor. This was evident by the production of IgM, IgG, and IgG2b, which bound specifically to tumor cells and led to specific tumor cell lysis in the presence of complement. Collectively, these data indicate that in vivo primed and in vitro activated B cells can be employed as effector cells for cancer therapy. The synergistic antitumor efficacy of cotransferred activated B effector cells and T effector cells represents a novel approach for cancer adoptive immunotherapy. The Journal of Immunology, 2009, 183: 3195-3203.
引用
收藏
页码:3195 / 3203
页数:9
相关论文
共 50 条
[31]   Collaboration between tumor-specific CD4+ T cells and B cells in anti-cancer immunity [J].
Guy, Thomas V. ;
Terry, Alexandra M. ;
Bolton, Holly A. ;
Hancock, David G. ;
Zhu, Erhua ;
Brink, Robert ;
McGuire, Helen M. ;
Shklovskaya, Elena ;
Fazekas de St Groth, Barbara .
ONCOTARGET, 2016, 7 (21) :30211-30229
[32]   Inhibition of Histone Lysine Methylation Enhances Cancer-Testis Antigen Expression in Lung Cancer Cells: Implications for Adoptive Immunotherapy of Cancer [J].
Rao, Mahadev ;
Chinnasamy, Nachimuthu ;
Hong, Julie A. ;
Zhang, Yuwei ;
Zhang, Mary ;
Xi, Sichuan ;
Liu, Fang ;
Marquez, Victor E. ;
Morgan, Richard A. ;
Schrump, David S. .
CANCER RESEARCH, 2011, 71 (12) :4192-4204
[33]   Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy [J].
Mousset, Charlotte M. ;
Hobo, Willemijn ;
Ji, Yun ;
Fredrix, Hanny ;
De Giorgi, Valeria ;
Allison, Robert D. ;
Kester, Michel G. D. ;
Falkenburg, J. H. Frederik ;
Schaap, Nicolaas P. M. ;
Jansen, Joop H. ;
Gattinoni, Luca ;
Dolstra, Harry ;
van der Waart, Anniek B. .
ONCOIMMUNOLOGY, 2018, 7 (10)
[34]   Republication: A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients With Incurable Pancreatic Cancer [J].
Yamaguchi, Yoshiyuki ;
Katata, Yousuke ;
Okawaki, Makoto ;
Sawaki, Akira ;
Yamamura, Masahiro .
ANTICANCER RESEARCH, 2022, 42 (02) :1181-1187
[35]   Intratumoral adoptive immunotherapy with tumor infiltrating Lymphocytes(TIL) in a melanoma patient leading to regression of local tumor mass. A case report [J].
Moller, P ;
Wittig, B ;
Schadendorf, D .
ANTICANCER RESEARCH, 1998, 18 (2B) :1237-1241
[36]   Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer [J].
Oh, David Y. ;
Kwek, Serena S. ;
Raju, Siddharth S. ;
Li, Tony ;
McCarthy, Elizabeth ;
Chow, Eric ;
Aran, Dvir ;
Ilano, Arielle ;
Pai, Chien-Chun Steven ;
Rancan, Chiara ;
Allaire, Kathryn ;
Burra, Arun ;
Sun, Yang ;
Spitzer, Matthew H. ;
Mangul, Serghei ;
Porten, Sima ;
Meng, Maxwell, V ;
Friedlander, Terence W. ;
Ye, Chun Jimmie ;
Fong, Lawrence .
CELL, 2020, 181 (07) :1612-+
[37]   Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells [J].
Han, Bohwa ;
Song, Yeonju ;
Park, Jeehun ;
Doh, Junsang .
JOURNAL OF CONTROLLED RELEASE, 2022, 343 :379-391
[38]   Cancer immunotherapy: In vivo imaging of adoptively transferred T cells in an immunocompetent host [J].
Sharma, Padmanee .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (32) :13977-13978
[39]   Recombinant Human Cyclophilin A in Combination with Adoptive T-cell Therapy Improves the Efficacy of Cancer Immunotherapy in Experimental Models in vivo [J].
Kalinina, Anastasiia A. ;
Kazansky, Dmitry B. ;
Khromykh, Ludmila M. .
BIOCHEMISTRY-MOSCOW, 2023, 88 (05) :590-599
[40]   Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model [J].
Contreras, Amanda ;
Beems, Megan, V ;
Tatar, Andrew J. ;
Sen, Siddhartha ;
Srinand, Prakrithi ;
Suresh, M. ;
Luther, Tahra K. ;
Cho, Clifford S. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6